To amend the Internal Revenue Code of 1986 to exclude from gross income certain compensation to clinical trial participants.

This bill excludes from gross income, for income tax purposes, amounts received as payment or reimbursement for participation in an approved clinical trial (i.e., a trial conducted for the prevention, detection, or treatment of cancer or other life-threatening disease or condition). This includes amounts paid or reimbursed for meals, lodging, or travel expenses.

Bill 118 hr 7090, also known as the "Clinical Trial Participant Compensation Exclusion Act," aims to amend the Internal Revenue Code of 1986 to exclude certain compensation received by individuals participating in clinical trials from their gross income.

The bill recognizes the important role that clinical trial participants play in advancing medical research and innovation. By excluding compensation received for participating in these trials from gross income, the bill seeks to incentivize more individuals to participate in clinical trials, ultimately leading to the development of new and improved medical treatments and therapies.

Under the provisions of the bill, compensation received by clinical trial participants for their time, travel expenses, and other related costs would not be subject to federal income tax. This would provide much-needed financial relief to individuals who volunteer for these trials and help remove a potential barrier to participation. Overall, the Clinical Trial Participant Compensation Exclusion Act aims to support and encourage participation in clinical trials, ultimately benefiting both individuals and the broader medical community.